Immunovaccine

The Company’s DepoVax™ platform is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. Immunovaccine has advanced two DepoVax™-based cancer vaccines into Phase 1 human clinical trials. The Company is also advancing a broad infectious diseases pipeline including vaccines in such indications as malaria, respiratory syncytial virus (RSV) and anthrax. In addition to the Company’s human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has key partnerships in the animal health sector including an agreement with Zoetis, former animal health division of Pfizer.
Company Growth (employees)
Type
Public
HQ
Halifax, CA
Founded
2000
Size (employees)
23 (est)
Immunovaccine was founded in 2000 and is headquartered in Halifax, CA

Immunovaccine Office Locations

Immunovaccine has an office in Halifax
Halifax, CA (HQ)
412 1344 Summer St

Immunovaccine Data and Metrics

Immunovaccine Financial Metrics

CAD

Market capitalization (25-Jul-2017)

147.4 m

Closing share price (25-Jul-2017)

1.2
Immunovaccine's current market capitalization is $147.4 m.

Immunovaccine Market Value History

Traffic Overview of Immunovaccine

Immunovaccine Online and Social Media Presence

Immunovaccine News and Updates

BRIEF-Immunovaccine awarded subcontract to evaluate depovax for development of malaria vaccine targets

* Awarded a subcontract by leidos to evaluate immunovaccine's depovax(tm) platform for development of peptide based malaria vaccine targets Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Immunovaccine Company Life and Culture

You may also be interested in